All In Biotech

Drug Trial Radar · NCT03855137

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress)

Last checked: Nov 20, 2026Latest source record: Feb 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 778 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

778

Actual

Start

Mar 11, 2019

Primary completion

Jan 20, 2022

Study completion Jan 20, 2022

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.

Conditions

  • Chronic Migraine

Interventions

  • Atogepant 30 mgDrug

    Tablets containing 30 mg atogepant

  • Atogepant 60 mgDrug

    Tablets containing 60 mg atogepant

  • PlaceboDrug

    30 mg/60 mg tablets containing atogepant-matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT PopulationTime frame: Baseline to Week 12
  2. Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand PopulationTime frame: Baseline to Week 12

Locations

150 sites in 17 countries. Site status is shown where the registry gives one.

  • Barrow Neuro Institute /ID# 236776

    Phoenix, Arizona

  • Baptist Health Center for Clinical Research /ID# 237361

    Little Rock, Arkansas

  • California Headache and Balance Center /ID# 236246

    Fresno, California

  • Wr-Pri Llc /Id# 236008

    Los Alamitos, California

  • Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 237692

    Newport Beach, California

  • Schuster Medical Research Institute /ID# 236447

    Sherman Oaks, California

  • Alpine Clinical Research Center /ID# 234346

    Boulder, Colorado

  • George Washington University Medical Faculty Associates /ID# 238011

    Washington D.C., District of Columbia

  • Accel Research Sites - St Petersburg Clinical Research Unit /ID# 237161

    St. Petersburg, Florida

  • Accel Research Sites - Tampa Clinical Research Unit /ID# 237485

    Tampa, Florida

  • Premiere Research Institute - Palm Beach /ID# 238192

    West Palm Beach, Florida

  • NeuroTrials Research Inc. /ID# 237364

    Atlanta, Georgia

  • Josephson-Wallack-Munshower Neurology - NE /ID# 238234

    Indianapolis, Indiana

  • Collective Medical Research /ID# 236400

    Prairie Village, Kansas

  • Ochsner Clinic Foundation /ID# 236543

    Covington, Louisiana

  • Beth Israel Deaconess Medical Center /ID# 237540

    Boston, Massachusetts

  • BTC of New Bedford /ID# 236384

    New Bedford, Massachusetts

  • Clinical Research Institute, Inc /ID# 238299

    Minneapolis, Minnesota

  • Headache Neurology Research Institute /ID# 236464

    Ridgeland, Mississippi

  • Nevada Headache Institute /ID# 236420

    Las Vegas, Nevada

  • Dartmouth-Hitchcock Medical Center /ID# 237444

    Lebanon, New Hampshire

  • Albuquerque Clinical Trials, Inc /ID# 236853

    Albuquerque, New Mexico

  • Albany Medical Center Rheumatology /ID# 236540

    Albany, New York

  • Dent Neurosciences Research Center, Inc. /ID# 237040

    Amherst, New York

  • Headache Wellness Center /ID# 236431

    Greensboro, North Carolina

  • Raleigh Neurology Associates /ID# 237141

    Raleigh, North Carolina

  • Stetson-University of Cincinnati /ID# 236453

    Cincinnati, Ohio

  • Abington Neurological Associates - Abington /ID# 236258

    Abington, Pennsylvania

  • Preferred Primary Care Physicians, Inc. /ID# 236439

    Pittsburgh, Pennsylvania

  • WR-ClinSearch /ID# 238288

    Chattanooga, Tennessee

  • Clinical Neuroscience Solutions - Memphis /ID# 237478

    Memphis, Tennessee

  • DiscoveResearch, Inc /ID# 236274

    Bryan, Texas

  • Texas Neurology /ID# 236359

    Dallas, Texas

  • University of Texas Southwestern Medical Center /ID# 236941

    Dallas, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic /ID# 236395

    Salt Lake City, Utah

  • J. Lewis Research, Inc. Foothill Family Clinic South /ID# 236297

    Salt Lake City, Utah

  • Highland Clinical Research /ID# 237816

    Salt Lake City, Utah

  • MedStar Georgetown Neurology /ID# 236324

    McLean, Virginia

  • Sentara Neurology Specialists - Virginia Beach /ID# 234349

    Virginia Beach, Virginia

  • Northwest Clinical Research Center /ID# 237581

    Bellevue, Washington

Showing 40 of 150 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.